Trial: 202104080

A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of thorium-227 labeled antibody-chelator conjugate BAY 2701439, in participants with advanced HER2-expressing tumors

Phase

I

Principal Investigator

Wahl, Richard

Disease Site

Breast; Esophagus; Stomach

Learn more about this study at: clinicaltrials.gov